An RNA alternative to human transferrin: A new tool for targeting human cells

Molecular Therapy Nucleic Acids

Volumn 1, Issue 5, 2012, Pages e21-

  Wilner, Samantha E ^a   Wengerter, Brian ^a   Maier, Keith ^a   Borba Magalhães, Maria De Lourdes ^b   Del Amo, David Soriano ^a   Pai, Supriya ^c   Opazo, Felipe ^d   Rizzoli, Silvio O ^d   Yan, Amy ^a   Levy, Matthew ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b SANTA CATARINA STATE UNIVERSITY   (Brazil)

^c UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^d EUROPEAN NEUROSCIENCE INSTITUTE   (Germany)

Author keywords

Aftamer; Liposome; SiRNA; SNALPs; Transferrin

Indexed keywords

EID: 84867032008     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2012.14     Document Type: Article

References (52)

1. Daniels, TR, Delgado, T, Helguera, G and Penichet, ML (2006). The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells. Clin Immunol 121: 159-176. (Pubitemid 44572972)
2. Daniels, TR, Delgado, T, Rodriguez, JA, Helguera, G and Penichet, ML (2006). The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin Immunol 121: 144-158. (Pubitemid 44592578)
3. Jones, AR and Shusta, EV (2007). Blood-brain barrier transport of therapeutics via receptor- mediation. Pharm Res 24: 1759-1771. (Pubitemid 47206625)
4. Head, JF, Wang, F and Elliott, RL (1997). Antineoplastic drugs that interfere with iron metabolism in cancer cells. Adv Enzyme Regul 37: 147-169. (Pubitemid 27371560)
5. Laske, DW, Muraszko, KM, Oldfield, EH, DeVroom, HL, Sung, C, Dedrick, RL et al. (1997). Intraventricular immunotoxin therapy for leptomeningeal neoplasia. Neurosurgery 41: 1039-49; discussion 1049.
6. Laske, DW, Youle, RJ and Oldfield, EH (1997). Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat Med 3: 1362-1368. (Pubitemid 28011036)
7. Weaver, M and Laske, DW (2003). Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J Neurooncol 65: 3-13. (Pubitemid 37441310)
8. Mendonça, LS, Firmino, F, Moreira, JN, Pedroso de Lima, MC and Simões, S (2010). Transferrin receptor-targeted liposomes encapsulating anti-BCR-ABL siRNA or asODN for chronic myeloid leukemia treatment. Bioconjug Chem 21: 157-168.
9. Sahoo, SK, Ma, W and Labhasetwar, V (2004). Efficacy of transferrin-conjugated paclitaxelloaded nanoparticles in a murine model of prostate cancer. Int J Cancer 112: 335-340. (Pubitemid 39244375)
10. Matsumura, Y and Maeda, H (1986). A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 46(12 Pt 1): 6387-6392. (Pubitemid 17221789)
11. Bartlett, DW, Su, H, Hildebrandt, IJ, Weber, WA and Davis, ME (2007). Impact of tumorspecific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci USA 104: 15549-15554. (Pubitemid 47502954)
12. Engler, JA, Lee, JH, Collawn, JF and Moore, BA (2001). Receptor mediated uptake of peptides that bind the human transferrin receptor. Eur J Biochem 268: 2004-2012. (Pubitemid 32852941)
13. Chen, CH, Dellamaggiore, KR, Ouellette, CP, Sedano, CD, Lizadjohry, M, Chernis, GA et al. (2008). Aptamer-based endocytosis of a lysosomal enzyme. Proc Natl Acad Sci USA 105: 15908-15913.
14. Magalhães, ML, Byrom, M, Yan, A, Kelly, L, Li, N, Furtado, R et al. (2012). A general RNA motif for cellular transfection. Mol Ther 20: 616-624.
15. Padilla, R and Sousa, R (1995). Mutant T7 RNA-polymerase as a DNA-polymerase. Embo Journal 14: 4609-4621.
16. Padilla, R and Sousa, R (1999). Efficient synthesis of nucleic acids heavily modified with non-canonical ribose 2'-groups using a mutantT7 RNA polymerase (RNAP). Nucleic Acids Res 27: 1561-1563. (Pubitemid 29206303)
17. Pieken, WA, Olsen, DB, Benseler, F, Aurup, H and Eckstein, F (1991). Kinetic characterization of ribonuclease-resistant 2'-modified hammerhead ribozymes. Science 253: 314-317. (Pubitemid 21917156)
18. Schmid, SL and Carter, LL (1990). ATP is required for receptor-mediated endocytosis in intact cells. J Cell Biol 111(6 Pt 1): 2307-2318. (Pubitemid 120014516)
19. Ritchie, RF, Palomaki, GE, Neveux, LM, Navolotskaia, O, Ledue, TB and Craig, WY (2002). Reference distributions for serum iron and transferrin saturation: a practical, simple, and clinically relevant approach in a large cohort. J Clin Lab Anal 16: 237-245.
20. Isselbacher, KJ, Braunwald, E, Wilson, JD, Martin, JB, Fauci, AS and Kasper, DL (1994). Harrison's Principles of Internal Medicine, 13th edn. McGraw-Hill: New York.
21. Young, SP, Bomford, A and Williams, R (1984). The effect of the iron saturation of transferrin on its binding and uptake by rabbit reticulocytes. Biochem J 219: 505-510. (Pubitemid 14136724)
22. Jeffs, LB, Palmer, LR, Ambegia, EG, Giesbrecht, C, Ewanick, S and MacLachlan, I (2005). A scalable, extrusion-free method for efficient liposomal encapsulation of plasmid DNA. Pharm Res 22: 362-372. (Pubitemid 40558494)
23. Zimmermann, TS, Lee, AC, Akinc, A, Bramlage, B, Bumcrot, D, Fedoruk, MN et al. (2006). RNAi-mediated gene silencing in non-human primates. Nature 441: 111-114.
24. Heyes, J, Palmer, L, Bremner, K and MacLachlan, I (2005). Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids. J Control Release 107: 276-287. (Pubitemid 41316290)
25. Whitehead, KA, Langer, R and Anderson, DG (2009). Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 8: 129-138.
26. Zhou, J and Rossi, JJ (2011). Cell-specific aptamer-mediated targeted drug delivery. Oligonucleotides 21: 1-10.
27. Dua, P, Kim, S and Lee, DK (2011). Nucleic acid aptamers targeting cell-surface proteins. Methods 54: 215-225.
28. Davis, ME (2009). The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol Pharm 6: 659-668.
29. Davis, ME, Zuckerman, JE, Choi, CH, Seligson, D, Tolcher, A, Alabi, CA et al. (2010). Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464: 1067-1070.
30. Calando Pharmaceuticals. Safety Study of CALAA-01 to Treat Solid Tumor Cancers. In: ClinicalTrialsgov [Internet] Bethesda (MD): National Library of Medicine (US) 20111006. Available from: URL of the record NLM Identifier: NCT00689065.
31. Yu, YJ, Zhang, Y, Kenrick, M, Hoyte, K, Luk, W, Lu, Y et al. (2011). Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci Transl Med 3: 84ra44.
32. Ni, X, Zhang, Y, Ribas, J, Chowdhury, WH, Castanares, M, Zhang, Z et al. (2011). Prostate- targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts. J Clin Invest 121: 2383-2390.
33. Zhou, J, Swiderski, P, Li, H, Zhang, J, Neff, CP, Akkina, R et al. (2009). Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells. Nucleic Acids Res 37: 3094-3109.
34. Zhou, J, Li, H, Li, S, Zaia, J and Rossi, JJ (2008). Novel dual inhibitory function aptamersiRNA delivery system for HIV-1 therapy. Mol Ther 16: 1481-1489.
35. Wheeler, LA, Trifonova, R, Vrbanac, V, Basar, E, McKernan, S, Xu, Z et al. (2011). Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras. J Clin Invest 121: 2401-2412.
36. McNamara, JO 2nd, Andrechek, ER, Wang, Y, Viles, KD, Rempel, RE, Gilboa, E et al. (2006). Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol 24: 1005-1015. (Pubitemid 44215395)
37. Dassie, JP, Liu, XY, Thomas, GS, Whitaker, RM, Thiel, KW, Stockdale, KR et al. (2009). Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat Biotechnol 27: 839-849.
38. Dhar, S, Gu, FX, Langer, R, Farokhzad, OC and Lippard, SJ (2008). Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc Natl Acad Sci USA 105: 17356-17361.
39. Farokhzad, OC, Cheng, J, Teply, BA, Sherifi, I, Jon, S, Kantoff, PW et al. (2006). Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci USA 103: 6315-6320.
40. Mann, AP, Bhavane, RC, Somasunderam, A, Liz Montalvo-Ortiz, B, Ghaghada, KB, Volk, D et al. (2011). Thioaptamer conjugated liposomes for tumor vasculature targeting. Oncotarget 2: 298-304.
41. Kang, H, O'Donoghue, MB, Liu, H and Tan, W (2010). A liposome-based nanostructure for aptamer directed delivery. Chem Commun (Camb) 46: 249-251.
42. Tan, L, Neoh, KG, Kang, ET, Choe, WS and Su, X (2011). PEGylated anti-MUC1 aptamerdoxorubicin complex for targeted drug delivery to MCF7 breast cancer cells. Macromol Biosci 11: 1331-1335.
43. Judge, AD, Robbins, M, Tavakoli, I, Levi, J, Hu, L, Fronda, A et al. (2009). Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice. J Clin Invest 119: 661-673.
44. Tekmira Pharmaceuticals Corporation. Dose Escalation Study to Determine Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous TKM-080301. In: ClinicalTrialsgov [Internet] Bethesda (MD): National Library of Medicine (US) 20111006. Available from: URL of the record NLM Identifier: NCT01262235.
45. (NCI) NCI. TKM 080301 for Primary or Secondary Liver Cancer. In: ClinicalTrialsgov [Internet] Bethesda (MD): National Library of Medicine (US) 20111006. Available from: URL of the record NLM Identifier: NCT01437007.
46. Akinc, A, Querbes, W, De, S, Qin, J, Frank-Kamenetsky, M, Jayaprakash, KN et al. (2010). Targeted delivery of RNAi therapeutics with endogenous and exogenous ligandbased mechanisms. Mol Ther 18: 1357-1364.
47. Jeffs, LB, Palmer, LR, Ambegia, EG, Giesbrecht, C, Ewanick, S and MacLachlan, I (2005). A scalable, extrusion-free method for efficient liposomal encapsulation of plasmid DNA. Pharm Res 22: 362-372. (Pubitemid 40558494)
48. Hall, B, Micheletti, JM, Satya, P, Ogle, K, Pollard, J and Ellington, AD (2009). Design, synthesis, and amplification of DNA pools for in vitro selection. Curr Protoc Nucleic Acid Chem Chapter 9: Unit 9.2.
49. Wong, I and Lohman, TM (1993). A double-filter method for nitrocellulose-filter binding: application to protein-nucleic acid interactions. Proc Natl Acad Sci USA 90: 5428-5432. (Pubitemid 23176173)
50. McGraw, TE and Subtil, A (2001). Endocytosis: biochemical analyses. Curr Protoc Cell Biol Chapter 15: Unit 15.3.
51. Reulen, SW, Brusselaars, WW, Langereis, S, Mulder, WJ, Breurken, M and Merkx, M (2007). Protein-liposome conjugates using cysteine-lipids and native chemical ligation. Bioconjug Chem 18: 590-596. (Pubitemid 46493534)
52. Collingwood, MA, Rose, SD, Huang, L, Hillier, C, Amarzguioui, M, Wiiger, MT et al. (2008). Chemical modification patterns compatible with high potency dicer-substrate small interfering RNAs. Oligonucleotides 18: 187-199.